7月8日，现代牙科回购10.00万股股票，每股回购均价4.36港元，共耗资约43.62万港元，本年累计回购 592.70万股，占总股本0.63%。 现代牙科是一家在港股上市的公司，专注于牙科领域。它在牙科产品的研发、生产和销售方面有着广泛 的业务布局。现代牙科的产品涵盖了多个方面，包括义齿、牙科设备及相关牙科材料等。在牙科行业 中，现代牙科凭借其技术研发能力、生产工艺以及广泛的销售网络占据一定的市场地位。其生产的义齿 产品能够满足不同客户的需求，无论是从质量还是从美观度等方面都具有一定的竞争力。公司在市场上 的表现也受到多种因素的影响，如牙科行业整体的发展趋势、技术创新、市场竞争格局以及全球经济环 境等。在全球范围内，随着人们对口腔健康的重视程度不断提高，牙科市场有着广阔的发展前景，现代 牙科也在这样的市场环境下不断发展并通过回购股票等方式来优化公司的资本结构和市场形象。 本文源自：金融界 作者：港股君 现代牙科近期回购情况 回购日期回购均价回购股数回购金额本年累计回购股数2025-07-084.36210.00万43.62万592.70万2025-07- 074.31610.00万43.16万582.70万 ...

订阅A股市场资讯 +订阅 A股牙科医疗板块盘初拉升，皓宸医疗封板涨停，爱迪特涨超5%，康惠制药、悦心健康、正海生物、 国瓷材料等均涨超2.5%。 ...

It has been about a month since the last earnings report for Labcorp (LH) . Shares have added about 2.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Labcorp due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out ...

Core Insights - Modern Dental (03600.HK) is actively implementing multi-dimensional strategies to capture market opportunities and increase sales despite a challenging macroeconomic environment [1] - The acquisition of Thailand's largest dental laboratory, Hexa Ceram Company Limited, is expected to enhance the company's product offerings and market coverage, allowing it to outperform domestic and international competitors [1] - The company is leveraging its production facilities in Thailand, Vietnam, and Dongguan to demonstrate resilience in an uncertain international trade environment and capitalize on global digitalization trends [1] Financial Performance - For the three months ending March 31, 2025, the total revenue of the group was approximately HKD 881.11 million, representing an increase of about 5.3% compared to HKD 837.00 million for the same period in 2024 [1] - The total sales volume increased by approximately 26.6% to about 672,000 units for the three months ending March 31, 2025, compared to approximately 531,000 units for the same period in 2024 [2] - Excluding sales from Hexa Ceram, the group's sales volume increased by about 0.9% to approximately 536,000 units, while excluding Micro Dental and Hexa Ceram, the sales volume rose by about 2.1% to approximately 479,000 units [2] Digital Solutions - The contribution from Hexa Ceram included approximately 14,298 cases of digital solutions, with the total number of digital solution cases produced in China, Thailand, and Vietnam increasing to about 223,587 cases, a rise of 28.4% compared to approximately 174,193 cases in the same period of 2024 [2] - The increase in digital solution cases is attributed to more customers adopting intraoral scanners [2]

Summary of Zimvi's Conference Call Company Overview - **Company**: Zimvi - **Industry**: Dental Implants and Digital Dentistry - **Key Products**: TSX implant, T3 Pro implant, Real Guide software, Implant Concierge, Puros Allografts, Immediate Molar Implant Core Points and Arguments 1. **Market Opportunity**: In the U.S., there are approximately 8 million candidates for tooth replacement, but only 25% receive dental implants, indicating significant growth potential in the market [4][5][6] 2. **Adoption and Education**: Zimvi focuses on increasing adoption of dental implants through training and education for both staff and referring dentists, emphasizing the importance of clinical outcomes and customer experience [5][6][7] 3. **Product Innovation**: 43% of Zimvi's sales come from products launched in the last three years, showcasing a strong innovation pipeline [9][58] 4. **Digital Dentistry**: The company is investing in digital solutions, including AI and cloud-based software, to enhance workflow and patient experience, with Real Guide software seeing a 39% growth in 2024 [10][24][29] 5. **Financial Performance**: Despite headwinds, Zimvi reported a 41% improvement in EBITDA and a 238% increase in EPS, indicating strong operational efficiency [35][36] 6. **Growth Projections**: For the full year, Zimvi anticipates flat to 3% growth in top-line revenue, with adjusted EBITDA growth of 17% and adjusted EPS growth of 31% to 55% [37] Additional Important Insights 1. **Market Dynamics**: The dental implant market is underpenetrated, and Zimvi aims to capture more market share through new product introductions and improved customer relationships [8][12] 2. **Full Arch Market**: Zimvi has increased its share in the full arch market from 5% to approximately 8.5-9%, with plans to further enhance this segment [22][44] 3. **Cost Management**: The company has improved gross margins by 360 basis points through cost reductions and operational efficiencies, with aspirations to reach over 70% gross margin in the long term [50][52] 4. **Pent-Up Demand**: There is potential for pent-up demand in the dental market as consumer sentiment improves and interest rates decrease, which could lead to accelerated growth [54][56] 5. **Customer Retention**: The renewal rate for Real Guide software exceeds 90%, indicating strong customer loyalty and satisfaction [61] Conclusion Zimvi is positioned for growth in the dental implant market through strategic product innovation, digital transformation, and operational efficiencies. The company is optimistic about capturing additional market share and improving financial performance in the coming years.

Envista (NVST) 2025 Conference May 28, 2025 01:50 PM ET Speaker0 We'll get going. Jon Block from Stifel. Good to see everyone again for the afternoon. And for our next session, we're excited to be rejoined by Envista's CEO, Paul Keel. Paul, thanks for coming. I'm sure you remember you were appointed CEO at Envista a little over a year ago and you did me a huge favor because we were really hoping Envista was going to come. You only had a month or so on the job and you still attended Jaws and Paul. So I'll st ...

Summary of Dentsply Sirona Conference Call Company Overview - Dentsply Sirona is a leading company in the dental market, with a global reach and significant international market presence [1] Key Financial Performance - Q1 2025 results exceeded guidance, with revenue down mid-single digits year-over-year primarily due to Byte [2][4] - EPS was well above guidance, indicating strong operational performance despite revenue challenges [2] Market Landscape - The overall dental market remains stable but has not returned to pre-COVID levels after five years [4][11] - Patient traffic is stable but still below pre-COVID levels, with slight degradation in customer sentiment noted [4][5] - Germany has shown decent performance and slight improvement in the last couple of quarters [7] Customer Sentiment and Behavior - Customer sentiment in the U.S. has shifted slightly from "not concerned" to "a little bit concerned," but this is more of a numerical shift than a significant change in behavior [5][9] - No significant changes in footfall or purchase intent reported by customers [10] Challenges in the Dental Market - Awareness around oral health and sensitivity to pricing are ongoing challenges affecting the dental market [12] - High interest rates have constrained capital equipment investments, particularly impacting the CTS (Capital Equipment) division [12][16] Division Performance and Growth Strategies - **CTS and Implants/Prosthetics**: Both divisions are expected to decline in 2025, accounting for nearly 50% of revenue. The company is focused on improving customer sentiment and investing in efficiency [14][16] - **DS Core Platform**: Significant investments have been made in the DS Core platform, with a 14% increase in users and a 25% increase in connected devices quarter-over-quarter [18][19] - **Implants**: The importance of the sales force in the implant community has been underestimated, and efforts are being made to improve sales rep training and customer engagement [20][21] - **Orthodontics**: Growth is expected to resume as the impact of the DSO loss is lapped, with double-digit growth reported in Europe for SureSmile [30][33] Margin and Expense Management - Despite negative revenue growth, all divisions reported year-over-year margin increases due to reduced expenditures and improved operational efficiency [35][36] - OpEx was down 14% year-over-year in Q1 2025, with expectations for continued reductions in the future [39][40] Future Outlook - The company aims to return to growth, with expectations for normalized growth in 2025 and acceleration into 2026 [42][44] - Continued focus on innovation and customer engagement is seen as critical for future success [44][46] Distributor Relationships - Ongoing discussions with key distributors, including Patterson, have deepened, with positive engagement noted [50][52] - The company is working to restore relationships with key distributors in Europe and the U.S. [51] Virtual Sales Force Initiative - A virtual sales force initiative has been launched, with approximately 100 reps making 2,000 calls daily and generating meaningful engagement with accounts [58][59] - The initiative aims to create demand independently of distributors and has already resulted in sales [64] Tariff Impact - The impact of U.S.-China tariffs on Dentsply Sirona is minimal, accounting for less than a couple of percentage points of revenue [67][68] - The company is taking proactive measures to mitigate potential tariff risks, including redistributing products to U.S. distribution sites [69][70]

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月9日，新医疗科技巨头 舒万诺 Solventum （纽交所代码：SOLV） 公布了2025年第一季度财报表现。该季度销售额为 21亿美元 （约143亿元人民币），同 比增长 2.7% ， 调整后的每股收益（EPS）为 1.34美元 ，均超出市场预期。 股价因此上涨 5% ，收于 70.02美元 。 自2024年4月从3M分拆以来， Solventum已迅速进入独立运营阶段，并在2025年第一季度交出了亮眼的财报。本文将深入分析舒万诺的财务表现、战略转型进展以 及面临的挑战和风险。 # 财务表现与未来展望 2025年第一季度， Solventum 在各大业务板块的表现强劲，具体财务数据如下： MedSurg（医疗外科） ： 销售额为 12.81亿美元 （约61%），同比增长 3.4% ，主要得益于 V.A.C.负压伤口治疗系统 和 Tegaderm透明敷料 的市场需求。 Dental Solutions（牙科解决方案） ： 销售额为 3.36亿美元 （约16%），同比增长 0.4% ，其中， SprintRay合作 ...

我是现代雅科的首席财务官关亦杰感谢大家今天参加今天的业绩分享会然后我见时间也差不多了可能我就现在就开始吧然后因为通常都会有些投资人对现代雅科不太熟悉 那我就可能简单先夸个几分钟去讲一下现代牙科的那个投资亮点然后我们现代牙科其实是在牙科行业里面的主要的业务是在那个益齿这个领域里面的就益齿这一块它有产品就有一个特点它是一个基本上是定制化的一个产品来的 然后整个流转也是非常快的然后在这个行业里面我们服务的客户其实就是牙医牙科诊所那些客户全都是一些专业医疗人员然后就是我们的客户了简单说打个比方如果病人掉了牙 他去看的是牙医然后牙医就会建议他一个疗程然后如果有需要做回一个疫诊的时候他牙医通常就会找我们这些疫诊服务商去帮忙把这个疫诊做好给到他们然后他们服务那个病人大概整个逻辑就是这样子然后这个行业呢我们是这个行业的全球里面的其中一家领导公司 然后基本上这个行业里面只有现代雅科能做到跨地域性的一个领导公司出来然后我们现在的业务基本上是48%的收入是从欧洲区的然后另外四分之一左右是在北美包括了加拿大跟美国然后另外22%左右就是大中华地区然后剩下的就是 澳大利亚跟新西兰占了另外的应该大概8%左右然后新加坡还有一些就是我们在开发 ...

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Daley - Vice President of Investor Relations Simon Campion - President & Chief Executive Officer Herman Cueto - Interim Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Erin Wright - Morgan Stanley Brandon Vazquez - William Blair David Saxon - Needham & Company Jeffrey Johnson - Baird Kevin Caliendo - UBS Michael Cherny - Leerink Partners Jonathan ...